Skip to main content

Drug Interactions between Afinitor Disperz and Sucraid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Afinitor Disperz and Sucraid. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Afinitor Disperz

A total of 547 drugs are known to interact with Afinitor Disperz.

Sucraid

A total of 0 drugs are known to interact with Sucraid.

Drug and food interactions

Moderate

sacrosidase food

Applies to: Sucraid (sacrosidase)

GENERALLY AVOID: The enzyme activity of sacrosidase is diminished if it is taken with acidic foods.

MANAGEMENT: The manufacturer recommends that the drug not be taken with fruit juice.

References (1)
  1. (2001) "Product Information. Sucraid (sacrosidase)." Orphan Medical
Moderate

everolimus food

Applies to: Afinitor Disperz (everolimus)

GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus. The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.

MANAGEMENT: Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.

References (1)
  1. (2009) "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer